The estimated Net Worth of Charles K Gayer is at least $2.44 Milion dollars as of 13 May 2024. Mr. Gayer owns over 30,000 units of Biocryst Pharmaceuticals stock worth over $2,377,230 and over the last 4 years he sold BCRX stock worth over $66,490. In addition, he makes $0 as Senior Vice President i Chief Commercial Officer at Biocryst Pharmaceuticals.
Sign up
Mr. Gayer BCRX stock SEC Form 4 insiders trading
Charles has made over 2 trades of the Biocryst Pharmaceuticals stock since 2022, according to the Form 4 filled with the SEC. Most recently he bought 30,000 units of BCRX stock worth $164,100 on 13 May 2024.
The largest trade he's ever made was buying 30,000 units of Biocryst Pharmaceuticals stock on 13 May 2024 worth over $164,100. On average, Charles trades about 5,157 units every 74 days since 2020. As of 13 May 2024 he still owns at least 307,533 units of Biocryst Pharmaceuticals stock.
You can see the complete history of Mr. Gayer stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Charles Gayer biography
Charles K. Gayer serves as Senior Vice President, Chief Commercial Officer of the Company. Mr. Gayer joined BioCryst in 2015 as vice president of global strategic marketing. Since July 2019 he has served as interim chief commercial officer, playing a key role in defining the strategy, and building the commercial operations, to support the launch of berotralstat, BioCryst's oral kallikrein inhibitor for hereditary angioedema (HAE). Prior to joining BioCryst, Mr. Gayer held several U.S. and global commercial leadership roles in highly competitive rare disease categories at Grifols and Talecris Biotherapeutics from 2007 through 2015. Prior to joining Talecris, he spent six years at GlaxoSmithKline in a range of marketing and sales roles. He received his B.A. from Princeton University and his M.B.A. from the Fuqua School of Business of Duke University.
How old is Charles Gayer?
Charles Gayer is 49, he's been the Senior Vice President i Chief Commercial Officer of Biocryst Pharmaceuticals since 2020. There are 19 older and 3 younger executives at Biocryst Pharmaceuticals. The oldest executive at Biocryst Pharmaceuticals Inc. is Robert Ingram, 77, who is the Independent Chairman of the Board.
What's Charles Gayer's mailing address?
Charles's mailing address filed with the SEC is 4505 EMPEROR BLVD., SUITE 200, DURHAM, NC, 27703.
Insiders trading at Biocryst Pharmaceuticals
Over the last 24 years, insiders at Biocryst Pharmaceuticals have traded over $76,362,383 worth of Biocryst Pharmaceuticals stock and bought 4,042,003 units worth $20,848,654 . The most active insiders traders include Partners L P/Ilbiotechnolog..., Brothers Life Sciences Capi... oraz Carl L Gordon. On average, Biocryst Pharmaceuticals executives and independent directors trade stock every 31 days with the average trade being worth of $542,329. The most recent stock trade was executed by Amy E Mc Kee on 24 June 2024, trading 8,600 units of BCRX stock currently worth $54,352.
What does Biocryst Pharmaceuticals do?
biocryst pharmaceuticals, a biotechnology company, designs, optimizes and develops novel small-molecule drugs that block key enzymes involved in infectious and rare diseases. founded in 1986, biocryst has more than 50 employees and is experiencing continued growth. the company’s headquarters are located in research triangle park, north carolina and its discovery center of excellence is in birmingham, alabama. with expertise in drug discovery, clinical development, regulatory affairs and product commercialization, we continue to advance our clinical programs and to generate new compounds from our own discovery engine. we are proud of our culture of engagement and accountability that rewards people for innovative thinking and achievement of key objectives. the commitment of biocryst remains unchanged. we continue to be passionate about developing and marketing novel therapeutics for patients with rare and serious diseases.
What does Biocryst Pharmaceuticals's logo look like?
Complete history of Mr. Gayer stock trades at Biocryst Pharmaceuticals
Biocryst Pharmaceuticals executives and stock owners
Biocryst Pharmaceuticals executives and other stock owners filed with the SEC include:
-
Jon Stonehouse,
President, Chief Executive Officer, Director -
Megan Sniecinski,
Senior Vice President, Chief Business Officer -
Alane Barnes,
Senior Vice President, Chief Legal Officer and Corporate Secretary -
Jon P. Stonehouse,
CEO, Pres & Exec. Director -
Yarlagadda Babu,
Senior Vice President - Drug Discovery -
William Sheridan,
Senior Vice President, Chief Medical Officer -
Dr. William P. Sheridan,
Chief Medical Officer & Sr. VP -
Dr. Yarlagadda S. Babu,
Chief Discovery Officer -
Stephen Aselage,
Independent Director -
Robert Ingram,
Independent Chairman of the Board -
Kenneth Lee,
Independent Director -
Nancy Hutson,
Independent Director -
George Abercrombie,
Independent Director -
Theresa Heggie,
Independent Director -
Helen Thackray,
Independent Director -
Dr. Helen M. Thackray FAAP, M.D.,
Chief R&D Officer -
Anthony Doyle,
Chief Financial Officer, Senior Vice President -
Alan Levin,
Independent Director -
Charles Gayer,
Senior Vice President, Chief Commercial Officer -
Allen Hodge,
Vice President and General Manager for the United States -
Michael Jones,
Executive Director - Finance, Principal Accounting Officer -
Alane P. Barnes,
Sr. VP, Chief Legal Officer & Corp. Sec. -
Michael L. Jones,
Exec. Director of Fin. & Principal Accounting Officer -
Dr. Elliott T. Berger,
Sr. VP of Regulatory Affairs -
Robert C. Stoner,
VP of HR -
John D. Bluth,
Sr. VP of Investor Relations & Corp. Communications -
Anthony Doyle,
Sr. VP & CFO -
Sanj K Patel,
Director -
Stanley C Erck,
Director -
Fred E Cohen,
Director -
Lynne Powell,
Senior VP - CCO -
Thomas R Ii Staab,
Senior Vice President and CFO -
Bros. Advisors Lp Baker Bro...,
-
John L Higgins,
Director -
Felix Baker Bros. Investmen...,
-
Zola P Horovitz,
Director -
Robert S Lowrey,
Controller, PAO -
Steven K Galson,
Director -
Steve Aselage,
Director -
Brothers Life Sciences Capi...,
-
David Mc Cullough,
VP -
Bros. Capital (Gp), Llcbake...,
-
Stephen R Biggar,
Director -
Stuart Grant,
SR VP & CFO -
Beth C Seidenberg,
Director -
William W Featheringill,
Director -
/ Tisch Capital (Gp), Llcba...,
-
Biotech Capital (Gp), Llcba...,
-
Capital (Gp), Llcbaker Juli...,
-
Mike Mills,
Principal Accounting Officer -
Partners L P/Ilbiotechnolog...,
-
Carl L Gordon,
Director -
Charles E Bugg,
CEO -
J Claude Bennett,
President -
John A Montgomery,
Director -
Jonathan M Nugent,
VP Corp Communications -
W James Alexander,
SR. VP, Chief Medical Officer -
Randall B Riggs,
VP Business Development -
Michael A Darwin,
CFO -
Randolph C Steer,
Director -
Joseph H Jr Sherrill,
Director -
William M Iii Spencer,
Director -
Charles A Sanders,
Director -
Peder Jensen,
Director -
Amy E Mc Kee,
Director -
Machelle Sanders,
Director -
Vincent Milano,
Director